Latest News and Press Releases

PharmAla completes private placement and concurrent debt settlement with Advisor.

PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024

PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.

PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials

PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference

PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range

PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme

PharmAla provides corporate update following AGM

PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.

PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans